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Hereditary angioedema (HAE) is a syndrome characterized
by recurrent angioedema of the skin and mucosa induced by
genetic mutations that result in increased bradykinin concen-
tration in the tissues. HAE presents high morbidity and
mortality, especially if not adequately treated, since patients
live with the risk of having laryngeal angioedema that can
lead to death due to asphyxia. Abdominal attacks are also
very disabling, and patients often inadvertently undergo
exploratory laparotomies.
There are approximately 10,000 rare diseases, many of
which are life threatening and neglected, having problematic
diagnosis and poor therapy. HAE is a good example of how
this reality can be changed, with the support and partnership
of academia, the pharmaceutical industry, government and
NGOs, so that barriers are overcome and common goals are
achieved. In the last decade, knowledge regarding HAE has
increased: approximately 30 consensuses/guidelines were
developed and published worldwide, referral centers spe-
cialized in the disease were structured, and educational
programmes for patients and their relatives were implemen-
ted. New drugs were developed, the effectiveness of which
have been proven in the prophylaxis and treatment of HAE
attacks. As a consequence, better diagnosis and treatment of
HAE have improved patients’ quality of life and decreased
disease morbidity and mortality.
The statement "Medicine is a science and an art" is attri-
buted to Sir William Osler, a physician with numerous scien-
tific contributions, including the recognition of HAE as a
hereditary disease. The development of guidelines based on
scientific evidence is practicing medicine as a science. Using
the guidelines as an orientation, but attending patients with
their various phenotypes in a personalized way, is an art.
The publication of the "Brazilian Guidelines for the Diagnosis
and Treatment of Hereditary Angioedema" in 2011 (1,2) was
a milestone that boosted the care, education and research in
HAE in the country. Knowledge about the disease improved,
patient diagnoses increased and were made earlier, and new
treatments became available, providing great improvement
in HAE management. However, we need to expand the
projects that are under development, making them more
homogenous and covering all regions of Brazil, as well as
promote new initiatives to keep ameliorating the status quo.
In this scenario, a group of experts from the Brazilian
Association of Allergy and Immunology (ASBAI) and the
Brazilian Group for the Study of Hereditary Angioedema
(GEBRAEH) updated the 2011 Guidelines. While 9 specialists
from 7 services participated in the first guidelines, 27 parti-
cipants representing 13 services elaborated the "Brazilian
Guidelines for the Diagnosis and Treatment of Hereditary
Angioedema - 2017" (3,4). In the 2017 guidelines, the flow-
charts and algorithms for the diagnosis and treatment of
HAE were updated, with the inclusion of new drugs that
became available in Brazil. The aim of the document is to
standardize the management of HAE in the country, addres-
sing the causes, classification, clinical features, warning signals,
diagnostic criteria, diagnostic laboratory tests, differential
diagnosis, long- and short-term prophylaxis, and acute
attack therapy. We would like to highlight some aspects of
the 2017 guidelines:
1. HAE is underdiagnosed and may have a higher pre-
valence than the currently estimated rate in the literature,
especially if we consider the HAE subtype with normal
C1-INH.
2. The document is innovative when it proposes warning
signals for HAE awareness, with the acronym "HAAAAE"
that facilitates disease recognition by health professionals.
HAAAAE stands for Heredity, recurrent Angioedema,
recurrent Abdominal pain, Absence of urticaria, Absence of
response to antihistamines and association with Estrogen.
3. Always giving priority to clinical history, the measure-
ment of C4 levels is the main screening test for HAE with
C1 inhibitor deficiency.
4. Angioedema may be a clinical manifestation of anaphy-
laxis or constitute a clinical entity by itself, and, in this
case, it may be considered a syndrome. The present guide-
lines describe a classification of angioedema based on two
main endotypes: the angioedema due to excess bradyki-
nin and the histaminergic angioedema, associated with
degranulation of basophils/mast cells.
5. Four variables should be analysed when considering long-
term prophylaxis: the frequency, severity, and impact of
HAE attacks on patients’ quality of life, as well as the
availability of proper medications to treat HAE attacks,
which may occur even with the prescription of long-term
prophylaxis. The development of new drugs to treat HAE
attacks was a major advance. Most likely, the next break-
through development will be new drugs for HAE long-
term prophylaxis.DOI: 10.6061/clinics/2018/e354
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6. The drug of choice for short-term prophylaxis, when indi-
cated, is plasma-derived C1-INH concentrate (pdC1-INH).
7. There was great progress with Icatibant and pdC1-INH
concentrate approval in Brazil, which are the drugs of
choice for HAE attack treatment. These therapies can be
used at home and should be available for all patients.
The authors of the "Brazilian Guidelines for the Diagnosis
and Treatment of Hereditary Angioedema - 2017" hope that
all readers enjoy the guidelines, which have been divided in
two parts; part one is being published in the present issue,
and part two will be published in a future issue. The
guidelines were developed to assist with the diagnosis and
treatment of HAE, to reduce HAE morbidity and mortality
and to improve patients’ quality of life.
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